Analysts at Citigroup on Monday added shares of TESARO Inc (NASDAQ: TSRO) to its "Citigroup's Focus List" while at the same time removing shares of Medivation Inc (NASDAQ: MDVN) from the same list.
Tesaro: Leadership Position
In a report published Tuesday, Barclays Capital analyst Geoffrey Meacham initiated coverage on Medivation Inc (NASDAQ: MDVN) with an Overweight rating and $130.00 price target.
In the report, Barclays Capital noted, “Medivation's Xtandi is now...
The prostate cancer experts at Medivation are getting into the hot field of checkpoint inhibitors for cancer, agreeing to pay Israel's CureTech as much as $335 million for the full rights to a promising Phase II asset.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.